Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Vorinostat in Newly Diagnosed Glioblastoma
NCT03426891Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2018
- Primary completion
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab and vorinostat in glioblastoma (GBM) (2 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Maximum Tolerated Dose at 12 weeks. Started Mar 2018; status: completed.
02
Drugs
pembrolizumabvorinostat
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03426891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03426891.